ATE232545T1 - Rezeptor spezifische atrio-natriuretische peptide - Google Patents

Rezeptor spezifische atrio-natriuretische peptide

Info

Publication number
ATE232545T1
ATE232545T1 AT95901112T AT95901112T ATE232545T1 AT E232545 T1 ATE232545 T1 AT E232545T1 AT 95901112 T AT95901112 T AT 95901112T AT 95901112 T AT95901112 T AT 95901112T AT E232545 T1 ATE232545 T1 AT E232545T1
Authority
AT
Austria
Prior art keywords
receptor
human
atrio
natriuretic peptides
receptor specific
Prior art date
Application number
AT95901112T
Other languages
English (en)
Inventor
David Lowe
Brian C Cunningham
David Oare
Robert S Mcdowell
John Burnier
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE232545T1 publication Critical patent/ATE232545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95901112T 1993-11-12 1994-11-04 Rezeptor spezifische atrio-natriuretische peptide ATE232545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15299493A 1993-11-12 1993-11-12
PCT/US1994/012591 WO1995013296A1 (en) 1993-11-12 1994-11-04 Receptor specific atrial natriuretic peptides

Publications (1)

Publication Number Publication Date
ATE232545T1 true ATE232545T1 (de) 2003-02-15

Family

ID=22545344

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901112T ATE232545T1 (de) 1993-11-12 1994-11-04 Rezeptor spezifische atrio-natriuretische peptide

Country Status (10)

Country Link
EP (1) EP0728147B1 (de)
JP (1) JP3989535B2 (de)
AT (1) ATE232545T1 (de)
AU (1) AU1934995A (de)
CA (1) CA2174517C (de)
DE (1) DE69432123T2 (de)
DK (1) DK0728147T3 (de)
ES (1) ES2194895T3 (de)
PT (1) PT728147E (de)
WO (1) WO1995013296A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
ZA979060B (en) * 1996-10-22 1999-04-09 Genentech Inc Receptor selective BNP
AU6820898A (en) * 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
US6013630A (en) * 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
CA2647146A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CN107405390A (zh) 2014-12-05 2017-11-28 阿雷克森制药公司 用重组碱性磷酸酶治疗癫痫
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
RU2754558C2 (ru) 2016-04-01 2021-09-03 Алексион Фармасьютикалз, Инк. Лечение мышечной слабости с помощью щелочных фосфатаз
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (de) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie (hpp) bei erwachsenen und jugendlichen
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
CA2045420A1 (en) * 1990-06-26 1991-12-27 Ruth F. Nutt Peptides having atrial natriuretic factor activity

Also Published As

Publication number Publication date
DE69432123D1 (de) 2003-03-20
EP0728147B1 (de) 2003-02-12
DK0728147T3 (da) 2003-06-10
PT728147E (pt) 2003-06-30
ES2194895T3 (es) 2003-12-01
DE69432123T2 (de) 2004-01-08
JPH09505049A (ja) 1997-05-20
JP3989535B2 (ja) 2007-10-10
EP0728147A1 (de) 1996-08-28
WO1995013296A1 (en) 1995-05-18
AU1934995A (en) 1995-05-29
CA2174517C (en) 2007-01-02
CA2174517A1 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
ATE232545T1 (de) Rezeptor spezifische atrio-natriuretische peptide
FR2697525B1 (fr) Peptides de fusion ayant une activité de liaison à la streptavidine.
ATE318912T1 (de) Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DE3851238D1 (de) Antikoagulierende Peptide.
DE68912268T2 (de) Elastomere polypeptide als vaskulare prothesematerialien.
DE59708952D1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
BG102817A (en) Modulators of factor traf asociated with tnf-receptor, their preparation and application
NO883731L (no) Isbrytende skip.
ES2104639T3 (es) Adnc para un peptido natriuretico de tipo c de rata, y proteina precursora.
DE69714475T2 (de) Neue (alpha-aminophosphino) peptide, verfahren zu ihrer herstellung und ihre therapeutische verwendung
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
DE69808717D1 (de) Atriale natriuretische peptide (anp) als zusatzstoff für peritonealdialyse
EP0970192A4 (de) Nukleinsäure, die für das algu protein von m. tuberculosis kodiert.
NO974713L (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.
DE69415548D1 (de) Haemoregulatorische penta-oder hexapeptide
AU5696994A (en) Acyclic, sulphureous peptides as analogs of the atrial natriuretic peptide
DE69420044D1 (de) Blutregulierende peptide
AU8752401A (en) A novel polypeptide, a humain protein synthesis initiation factor sub-unit 2 beta 16.5 and the polynucleotide encoding the polypeptide
MA21633A1 (fr) Sunthese peptidiques en phase solide.
FI893211A (fi) Antihypertensiva, n-terminala eteraminodiolamino-syraderivat.
UA35624C2 (uk) МОЛЕКУЛА ДНК, ЩО КОДУЄ ПРОТЕЇН TGF-<font face="Symbol">b</font>-РОДИНИ, ВЕКТОР, L-КЛІТИНА, ПРОТЕЇН TGF-<font face="Symbol">b</font>-РОДИНИ, СПОСІБ ЙОГО ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, МОНОКЛОНАЛЬНЕ АНТИТІЛО
DE68904904D1 (de) Synthetische scm-aktive, krebserkennende peptide.
ATA98792A (de) Peptide, die antikörper binden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728147

Country of ref document: EP